This study will evaluate the response rates in the primary tumor and metastatic sites from patients with newly diagnosed locally advanced or oligometastatic prostate cancer treated with combination androgen deprivation therapy (ADT) and 3 cycles of docetaxel chemotherapy followed by prostatectomy. Each patient will get PET/MRs before receiving any treatments for their prostate cancer, 3-5 weeks after their last dose of chemotherapy, and then again 4-6 weeks after their prostatectomy. This is done to evaluate PSMA PET/CT and PET/MRI imaging as a method for determining treatment response in primary prostate cancer and metastatic lesions after ADT and docetaxel administrations.
This project was funded by: Department of Defense
The term of this project was: February 2018 to January 2019
The number of subjects scanned during this project was: 30